Repeated-dose Behavioral Intervention to Reduce Opioid Overdose

San Francisco Department of Public Health268 enrolled

Overview

REBOOT is a randomized trial of a repeated-dose brief intervention to reduce overdose and risk behaviors among naloxone recipients with opioid use disorder. It includes an established overdose education curriculum within an Informational-Motivation-Behavior (IMB) model. This study will test the efficacy of REBOOT vs attention-control.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

PREVENTION

Masking

SINGLE

Enrollment

268

Conditions

Opioid-Related Disorders Drug Overdose

Interventions

REBOOTBEHAVIORAL

The brief counseling intervention will utilize Motivational Interviewing and skills-building techniques to modify personal overdose risk behaviors and develop skills as a peer responder for witnessed overdose. The counselor will draw upon themes of safer substance use to address overdose risk behaviors and determine readiness for change in substance use.

Eligibility

Sex: ALLMin age: 18 YearsMax age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Age 18-65 years * Characteristics of opioid use history * Previously received take-home naloxone * No life-threatening illness likely to progress clinically during trial * Able/willing to provide informed consent and locator information, communicate in English, and adhere to visit schedule Exclusion Criteria: * Suicidal ideation * Participating in another interventional study that could possibly impact the study's outcomes of interest * Planning to leave San Francisco/Boston metro area during study * Previously exposed to REBOOT counseling intervention * Any condition that, in the Principal Investigator's judgment, interferes with safe study participation or adherence to study procedures

Locations (2)

San Francisco Department of Public Health

San Francisco, California, United States

Boston Medical Center

Boston, Massachusetts, United States

Outcomes

Primary Outcomes

Number of Overdose Events

Number of overdose events will be measured by self-report via timeline follow-back (TLFB) assessment, ED/EMS records, and Vital records.

Time frame: 16 Months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.